Discovery of a Quinazoline-Based Nav1.7 Inhibitor with MicroED-Confirmed Absolute Configuration and Oral Efficacy in Rodent Models of Neuropathic Pain
Selective Nav1.7 inhibition is a genetically validated, non-opioid strategy for chronic neuropathic pain. Herein, we report the structure-guided discovery of a quinazoline-based Nav1.7 inhibitor series. From a focused-library hit A1 (IC50 = 15.2 μM), systematic SAR across 19 analogs yielded the chiral lead (R)-(+)-A1...